Xcout Intel
Beacon Biosignals
Beacon Biosignals is a healthtech company that uses EEG data, digital biomarkers, and machine learning to characterize brain activity and support neuroscience research and clinical drug development. It serves pharmaceutical and biotechnology companies, academic researchers, and clinical-trial teams working on neurological and psychiatric disorders.
Subscribe to see Beacon Biosignals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Beacon Biosignals at a glance
Beacon Biosignals is a biotech company headquartered in France. It has raised at least $133.1M across the 2 funding rounds on record. Its most recent funding round raised $103.3M in October 2025. Xcout tracks 19 named people at Beacon Biosignals, including David Matthews (Chief Business Officer). Xcout recorded 57 job postings from Beacon Biosignals in the last 90 days.
Beacon Biosignals leadership
- David MatthewsChief Business Officer
- Matt AlkaitisChief Clinical Officer
- Jacob DonoghueCEO & Co-Founder
- Jarrett RevelsCTO & Co-Founder
- Alex ChanVP of Analytics and Machine Learning
- Allison BralyVP of Clinical Strategy and Operations
13 more named people on record for Beacon Biosignals, with roles, board committees and tenure — see the full roster →
Beacon Biosignals funding rounds
At least $133.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $103.3M | — | |
| SEC Form D filing | $29.9M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Beacon Biosignals
Xcout recorded 57 job postings from Beacon Biosignals in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Beacon Biosignals's hiring signals →
Hiring vs the trend
Based on 45 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Beacon Biosignals’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Beacon Biosignals competitors
A few of Beacon Biosignals's closest competitors — see the full list of competitors and alternatives →
Indivi AG is a biotechnology research company headquartered in Basel, Switzerland. It focuses on pioneering the future of precision neurology through digital biomarkers for clinical research and patient monitoring, dedicated to unlocking the potential of digital measurements in drug development.
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Organoid Therapeutics, Inc. is a biotechnology contract research organization (CRO) that provides human brain tissue models, neuronal phenotyping, drug screening, and machine learning-based analytical services. The company serves pharmaceutical, biotech, and academic researchers by conducting pre-clinical research and translational studies to evaluate drug efficacy, neurotoxicity, and neurological disease models.
BenevolentAI provides an artificial intelligence platform and life science intelligence tools designed to assist scientists and pharmaceutical executives in drug discovery and research and development decision-making. The company leverages proprietary technology and machine learning to analyze biological data and support complex R&D processes.
BioROSA Technologies is a biotechnology company that develops a blood-based metabolomics and machine learning platform for the early diagnosis and assessment of Autism Spectrum Disorder. Founded in 2018, the company focuses on creating biologically-based screening and diagnostic standards to detect ASD in young children.
Durin Life Sciences develops Duritect™, a blood-based test that combines autoantibody biomarkers with machine learning technology to assess patients' risk of having Alzheimer's disease or Parkinson's disease. The company provides laboratory analysis services to process these blood samples and deliver risk score reports to physicians and patients.
Get Beacon Biosignals's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Beacon Biosignals in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access